# Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases

> **NCT00204581** · PHASE2 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 51 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Interleukin-2 (Proleukin)

## Key facts

- **NCT ID:** NCT00204581
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2009-01
- **Final completion:** 2009-12
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2011-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00204581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00204581, "Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00204581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*